Latest News
GSK Plummets After Failed Cough Drug Trial Wipes Out £2.36B
GSK shares fell 3% after a phase III trial failure for its chronic cough drug camlipixant erased £2.36 billion in market value, more than the cost of acquiring BELLUS.
FTSE 100 Shields Against Tech Rout; Burberry Dips on Travel Caution
The FTSE 100 opened down 0.25% but outperformed as its low tech weighting cushioned the impact of a global chip selloff. Burberry fell 5.2% despite 5% sales growth, with CFO citing tourism effects.
Lloyds Shares Decline as Higher Buyback Price Raises Strategic Concerns
Lloyds shares dipped 2.2% as the average buyback price rose 14.9% from Q1, reducing the impact of share repurchases and raising strategic questions.
EGYM-Playlist $7.5B Merger Targets Healthcare and Corporate Fitness Spend
EGYM's $7.5 billion merger with Playlist aims to tap into healthcare and corporate budgets, leveraging data and connected fitness to unlock new revenue streams beyond memberships.
Eurowag Shares Slide 7.4% After TA Associates Halves Stake
Eurowag shares fell 7.4% to 100p after TA Associates sold 30 million shares, reducing its stake to 12.7% and halving its original block since September.
Alphabet Loses $200B on Gemini 3.5 Pro Delay, AI Strategy Questioned
Alphabet shares fell 4.44% on Thursday, erasing nearly $200 billion in market value, as reports of a delay in the Gemini 3.5 Pro launch raised doubts about the company's AI investment strategy.
JPMorgan Backs $2.5B Shipbuilding Deal, Aims to Boost Maritime Sector
JPMorgan Chase (JPM) is providing $24 million in funding for a $2.5 billion shipbuilding deal between Rhoads Industries and Electric Boat, a General Dynamics subsidiary.
SpaceX Stock Plunges After Starship Abort, $53B Value Erased
SpaceX shares dropped 4.52% in premarket trading after the Starship Flight 13 abort, erasing about $53 billion in implied equity value.
TrumpRx Program Shows Limited Big Pharma Impact
TrumpRx's 79 presidential deals cover just 10% of branded drugs from 17 pharma firms, far below the touted 800. Major drugs like Ibrance and Biktarvy are excluded, limiting investor risk.
Defense Boom Propels Saab to Record Q2 Profit; Tariff and Energy Jitters Weigh on US Futures
Saab's Q2 profit soared 41% to 2.79B SEK, beating estimates, as defense orders surged 141% amid European rearmament. US futures slipped on tariff and energy cost concerns.